Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy
Information source: Stanford University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pregnancy Complications
Intervention: Dexcom Seven Plus Continuous Glucose Monitoring System (Device)
Phase: N/A
Status: Completed
Sponsored by: Stanford University Official(s) and/or principal investigator(s): Yasser Yehia El-Sayed, Principal Investigator, Affiliation: Stanford University
Summary
We hope to clarify how betamethasone affects glucose levels in the mother in the days after
receiving the drug. This understanding will hopefully allow us to better anticipate the risk
of maternal hyperglycemia and therefore establish more appropriate monitoring of maternal
glucose to prevent maternal and neonatal complications of hyperglycemia.
Clinical Details
Official title: Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Episodes of hyperglycemia
Secondary outcome: Neonatal hypoglycemia
Detailed description:
Pregnant patients who are undergoing inpatient betamethasone therapy as part of their
clinical care will be eligible for the study. Once the clinical team and patients have
agreed to pursue betamethasone therapy, the patients' treating physician or nurse will
inquire if the patient is interested in participating in our study protocol. Those patients
who are interested in participation will be consented by either a member of the treatment
team or the study team. Prior to receiving the first betamethasone dose, a soft sensor for
continuous glucose monitoring system (CGMS) will be inserted superficially under the skin.
For those patients who will be receiving a scheduled course of betamethasone, the sensor may
be inserted up to 24 hours prior to the betamethasone administration. The patient will be
instructed on how to wear and care for the device. She will wear the CGMS for the duration
of her hospitalization or for up to 7 days total, whichever time period is shorter. For
those patients who are diabetic, they will receive normal finger stick blood glucose (FSBG)
monitoring and insulin therapy as determined by their treating physicians. Those patients
who are not diabetic will need to have 2 FSBG checks each day to correlate with the device.
Abnormal values will be reported to the patients' treating physician and addressed by the
treating physician. Prior to being discharged from the hospital, the patient will have the
device removed. The patient will otherwise be treated routinely. We will record baseline
demographic information and medical history from each of the women. We will also record
information from the neonates' newborn medical records.
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:- 18 years of age or older
- Receiving betamethasone as part of routine clinical care.
- Pregnancy between 23+5 and 35+0 weeks
Exclusion Criteria:- Less than 18 years old.
- Major fetal anomalies
- Use of steroid medications in the past 2 weeks.
Locations and Contacts
Stanford University School of Medicine, Stanford, California 94305, United States
Additional Information
Maternal glucose response to betamethasone administration
Starting date: July 2010
Last updated: March 30, 2015
|